Ryan Hasson

An AI sell-off pulled Alphabet stock back toward its 200-day moving average near $340, testing a breakout setup built on the strong reception of its Gemini 4 Argon model.

Rocket Lab shares fell nearly 7% after the company delayed Neutron rocket's debut to 2027, breaking key technical support as analysts trimmed price targets but mostly kept bullish ratings.

Berkshire Hathaway's $330 million private placement in Bending Spoons sent shares up 40%, but its $33 entry price is far below the current price, and analysts rate the stock a Hold.

AI and memory stocks like Nebius, SK hynix, Intel, EWY, and DRAM have fallen sharply amid sector-wide selling, with each now testing key oversold support levels that could trigger a relief bounce.

Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.

GM beat Q3 estimates and announced a $20 billion buyback, but shares fell nearly 7% as unchanged EBIT guidance and North America-reliant profit raised growth concerns.

Lam Research posted record fiscal Q1 2027 results and raised its 2026-2027 wafer fabrication equipment spending forecasts, signaling chipmakers' capital spending plans remain intact despite a stock sell-off.

Lockheed Martin beat Q3 estimates and raised 2026 guidance, with its backlog hitting a record $292 billion, driven mainly by Missiles and Fire Control orders like PAC-3 and THAAD.

Ryan Hasson, MarketBeat 5 min read Key Points Interested in Lockheed Martin Corporation? Here are five stocks we like better.

While chip stocks slide, cybersecurity and software names like HACK, IGV, Microsoft, CrowdStrike, and Palantir hold near highs, suggesting a rotation within tech rather than a broad exit.